美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Invesco Nasdaq Biotechnology ETF

34.82

+0.34801.01%

盤後：34.820.00000.00%19:30 EDT

成交量：1.41萬

成交額：48.94萬

市值：9,679.96萬

市盈率：- -

高：34.92

開：34.52

低：34.42

收：34.47

52周最高：36.84

52周最低：23.42

股本：278.00萬

流通股本：278.00萬

量比：0.80

換手率：0.51%

股息：0.26

股息率：0.74%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

ST人福：RFUS-949片進入II期臨床試驗研究

甘李藥業(603087.SH)獲得GZC8072片新適應症《藥物臨床試驗批准通知書》

ETF日報(09.03)丨政策利好持續催化創新藥板塊「小非農」數據爆冷短期支撐金價

甘李藥業：GZC8072片獲2型糖尿病臨床試驗批准

ST人福(600079.SH)：RFUS-949片進入II期臨床試驗研究

創新藥概念局部回暖

A股創新藥概念局部回暖，千金藥業尾盤漲停，德展健康此前封板，諾誠健華、迪哲醫藥、百利天恒漲幅居前。

百奧賽圖與齊魯製藥達成全人納米抗體分子非排他授權合作，支持神經領域創新藥物開發

國內創新藥企中報歸母淨利增近九成！恒生創新藥ETF華泰柏瑞（520500）連續2個交易日獲資金加倉

創新藥企密集進入臨床數據驗證期，石藥集團升逾4%！華寶基金港股通創新藥ETF（520880）再收半年線！

摩根大通投行聯席負責人：併購交易業務有望迎來創紀錄年份。

首個國產IL-17A/F雙靶點抑制劑獲批，這一40年來「有研究無產品」的靶點迎臨床突破｜掘金創新藥

每日经济新闻

創新藥半年報冰火兩重天：百濟神州一款藥賣了161億元、六成藥企還在求生，「賣藥」仍是終極命題

每日经济新闻

歐康維視生物-B(01477)：OT-211 III期臨床試驗完成患者入組

安進（AMGN）罕見病藥物Tavneos將於27年3月1日被徹底撤銷英國上市許可

海西新藥：已提交自研創新藥HX9428臨床試驗申請

諾華集團：高效口服BTK抑制劑瑞米布替尼在III期RMS臨床試驗中顯著降低複發率安全性表現良好

眾生藥業(002317.SZ)：昂拉地韋片新增適應症臨床試驗申請獲受理

國家藥監局正式啓動滴眼劑一致性評價工作

高盛9月「確信名單」更新：美股納入福泰製藥(VRTX.US) 歐股力推萊茵、Adyen和塔蘭克斯

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/hant/stock/IBBQ/news?page=9"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IBBQ","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","market":"US","secType":"STK","nameCN":"Invesco Nasdaq Biotechnology ETF","latestPrice":34.82,"timestamp":1789416000000,"preClose":34.472,"halted":0,"volume":14094,"hourTrading":{"tag":"盘后","latestPrice":34.82,"preClose":34.82,"latestTime":"19:30 EDT","volume":36,"amount":1244.0123,"timestamp":1789428600873,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.01009514968670222,"floatShares":2780001,"shares":2780001,"eps":0,"marketStatus":"已收盤","change":0.348,"latestTime":"09-14 16:00:00 EDT","open":34.52,"high":34.92,"low":34.42,"amount":489401.81775,"amplitude":0.014505,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789459200000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":34.472,"sharesOutstanding":2520001,"nav":34.43989,"aum":95742928.63989,"dividendRate":0.007412,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":34.82,"preClose":34.82,"latestTime":"19:30 EDT","volume":36,"amount":1244.0123,"timestamp":1789428600873,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.801497,"impliedVol":0.1149,"impliedVolPercentile":0.4861},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBBQ\",,,,,undefined,":{"symbol":"IBBQ","floatShares":2780001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.801497,"shares":2780001,"dividePrice":0.2581,"high":34.92,"amplitude":0.014505,"preClose":34.472,"low":34.42,"week52Low":23.42,"pbRate":"--","week52High":36.84,"institutionHeld":0,"latestPrice":34.82,"eps":0,"divideRate":0.007412,"volume":14094,"delay":0,"ttmEps":0,"open":34.52,"prevYearClose":28.3962,"prevWeekClose":34.472,"prevMonthClose":35.4742,"prevQuarterClose":32.66,"fiveDayClose":36.05,"twentyDayClose":33.8122,"sixtyDayClose":29.94},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBBQ\",params:#limit:5,,,undefined,":[{"date":"2026-06-22","symbol":"IBBQ","amount":0.03422,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-06-22","defaultRemindTime":1782135000000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-06-26","payableDate":"2026-06-22","currency":"USD","dateTimestamp":1782100800000,"payDate":"2026-06-26"},{"date":"2026-03-23","symbol":"IBBQ","amount":0.03609,"announcedDate":"2026-03-20","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-03-23","defaultRemindTime":1774272600000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-03-27","payableDate":"2026-03-23","currency":"USD","dateTimestamp":1774238400000,"payDate":"2026-03-27"},{"date":"2025-12-22","symbol":"IBBQ","amount":0.0906,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-26","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-26"},{"date":"2025-09-22","symbol":"IBBQ","amount":0.09576,"announcedDate":"2025-09-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-22","defaultRemindTime":1758547800000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-26","payableDate":"2025-09-22","currency":"USD","dateTimestamp":1758513600000,"payDate":"2025-09-26"},{"date":"2025-06-23","symbol":"IBBQ","amount":0.0287,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-23","defaultRemindTime":1750685400000,"name":"Invesco Nasdaq Biotechnology ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-06-27","payableDate":"2025-06-23","currency":"USD","dateTimestamp":1750651200000,"payDate":"2025-06-27"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBBQ\",market:\"US\",,,undefined,":[{"executeDate":"2021-09-20","recordDate":"2021-09-21","paymentDate":"2021-09-30","value":0.04324,"currency":"USD"},{"executeDate":"2021-12-20","recordDate":"2021-12-21","paymentDate":"2021-12-31","value":0.10511,"currency":"USD"},{"executeDate":"2022-03-21","recordDate":"2022-03-22","paymentDate":"2022-03-31","value":0.03778,"currency":"USD"},{"executeDate":"2022-06-21","recordDate":"2022-06-22","paymentDate":"2022-06-30","value":0.04264,"currency":"USD"},{"executeDate":"2022-09-19","recordDate":"2022-09-20","paymentDate":"2022-09-23","value":0.03769,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBBQ\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBBQ\",pageSize:20,pageCount:9,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664820856","title":"ST人福：RFUS-949片進入II期臨床試驗研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2664820856","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664820856?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 16:37","pubTimestamp":1788424652,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBJ","BMED","MDTX","IBBQ","PSYK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664270568","title":"甘李藥業(603087.SH)獲得GZC8072片新適應症《藥物臨床試驗批准通知書》","url":"https://stock-news.laohu8.com/highlight/detail?id=2664270568","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664270568?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 16:31","pubTimestamp":1788424286,"startTime":"0","endTime":"0","summary":"智通财经APP讯，甘李药业(603087.SH)发布公告，公司全资子公司甘李药业山东有限公司于近日收到国家药品监督管理局下发的关于在研药品GZC8072片的《药物临床试验批准通知书》，同意本品开展2型糖尿病适应症的临床试验。GZC8072片是甘李药业自主研发的新一代偏向型超长效多肽口服周制剂。该分子依托公司NovaPeptide多肽技术平台与SupOraTide口服多肽技术平台，在提升分子活性、延长半衰期的基础上，同时显著改善口服生物利用度，从而有望支持每周一次口服给药的方案。截至公告披露日，全球范围内尚无用于2型糖尿病的GLP-1口服周制剂片剂获批上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491480.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["MDTX","PSYK","BK0239","BMED","IBBJ","603087","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664820831","title":"ETF日報(09.03)丨政策利好持續催化創新藥板塊 「小非農」數據爆冷短期支撐金價","url":"https://stock-news.laohu8.com/highlight/detail?id=2664820831","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664820831?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 16:30","pubTimestamp":1788424202,"startTime":"0","endTime":"0","summary":"国家医保局政策释放利好信号，创新药板块表现突出；美国ADP就业数据不及预期影响，黄金股相关ETF集体回升。截至收盘，恒生指数跌0.39%，报25213.31点，全日成交额1993.82亿港元；恒生科技指数跌1.08%，报4468.48点。国家医保局召开新闻发布会，发布按病种付费3.0版分组方案和技术规范，这一举措被视为对创新药板块的直接利好。因第二季净息差有所改善，信达国际短期看好内银股。中信证券表示，7月底以来，海外发达市场国债收益率普遍飙升。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491477.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["MGCmain","DUST","GDXD","GLDM","CERY","LNGR","OUNZ","IAU","UGL","UYM","CMDT","GBUG","RING","FGLD","GDX","CEF","AAAU","PALL","GCmain","NANR","PYZ","SGDJ","02840","IAUI","EPU","BEGS","MEDX","DZZ","IAUM","BTGD","SGOL","DBC","GDE","XLBI","FGDL","GOAU","YGLD","DGP","BAR","SGDM","06978","IBBQ","SHNY","159992","JNUG","SImain","USG","GDXY","DULL","VGFPF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664716827","title":"甘李藥業：GZC8072片獲2型糖尿病臨床試驗批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2664716827","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664716827?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 16:29","pubTimestamp":1788424183,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["MDTX","IBBQ","IBBJ","PSYK","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664279758","title":"ST人福(600079.SH)：RFUS-949片進入II期臨床試驗研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2664279758","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664279758?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 16:12","pubTimestamp":1788423169,"startTime":"0","endTime":"0","summary":"智通财经APP讯，ST人福(600079.SH)发布公告，公司控股子公司宜昌人福药业有限责任公司(简称“宜昌人福”，公司持有其80%的股权)研发的RFUS-949片近日进入II期临床试验研究。试验名称：评价RFUS-949片用于腹部手术术后镇痛的多中心、随机、双盲、平行、安慰剂对照的疗效和安全性研究试验目的：评价RFUS-949片用于术后镇痛的疗效和安全性，探索RFUS-949片用于术后镇痛的用法用量。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491467.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0012","BK0070","IBBQ","BK0096","600079","IBBJ","PSYK","BK0188","BMED","BK0028","BK0239","BK0185","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664242468","title":"創新藥概念局部回暖","url":"https://stock-news.laohu8.com/highlight/detail?id=2664242468","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664242468?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 14:59","pubTimestamp":1788418780,"startTime":"0","endTime":"0","summary":"创新药概念局部回暖","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609033864003250.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609033864003250.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IBBQ","MEDX","06978","BK1161","BK1574","LNGR","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664245108","title":"A股創新藥概念局部回暖，千金藥業尾盤漲停，德展健康此前封板，諾誠健華、迪哲醫藥、百利天恒漲幅居前。","url":"https://stock-news.laohu8.com/highlight/detail?id=2664245108","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664245108?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 14:58","pubTimestamp":1788418691,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","LNGR","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664782740","title":"百奧賽圖與齊魯製藥達成全人納米抗體分子非排他授權合作，支持神經領域創新藥物開發","url":"https://stock-news.laohu8.com/highlight/detail?id=2664782740","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664782740?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 14:23","pubTimestamp":1788416580,"startTime":"0","endTime":"0","summary":"北京2026年9月3日 /美通社/ -- 百奥赛图（北京）医药科技股份有限公司于2026年9月2日宣布，公司近期与齐鲁制药有限公司签署全人纳米抗体分子非排他授权合作协议。根据协议，百奥赛图将向齐鲁制药授权一款全人纳米抗体分子，用于支持其在神经领域创新药物项目中的研发探索。通过此次授权，齐鲁制药可结合其自身研发策略，对相关纳米抗体分子开展进一步研究和开发，后续项目的开发形式将根据项目特点和治疗需求灵活推进。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"prnasia","url":"http://wwwold.prnasia.com/story/archive/5039953_ZH39953_1","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/5039953_ZH39953_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["688796","BK1191","06978","IBBQ","01477","02315","MEDX","BK1161","BK0216","LNGR","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664500829","title":"國內創新藥企中報歸母淨利增近九成！恒生創新藥ETF華泰柏瑞（520500）連續2個交易日獲資金加倉","url":"https://stock-news.laohu8.com/highlight/detail?id=2664500829","media":"新浪基金","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664500829?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 13:37","pubTimestamp":1788413820,"startTime":"0","endTime":"0","summary":"全球创新药领域近期迎来密集催化。国内创新药企中报季业绩密集兑现。目前A股市场上仅有的跟踪恒生创新药指数的ETF——恒生创新药ETF华泰柏瑞已连续2个交易日获得资金净流入，7月以来日均成交额高达20.15亿元，最新份额、规模分别为18.99亿份、26.97亿元。华泰柏瑞基金是国内首批ETF管理人，在指数投资领域深耕超19年，为投资者打造了沪深300ETF华泰柏瑞、A500ETF华泰柏瑞等投向透明、交易便捷、费率低廉的指数工具。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2026-09-03/doc-iniqpqxy2132359.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","BK1161","IBBQ","06978","LNGR","MEDX","520500","159992"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664231028","title":"創新藥企密集進入臨床數據驗證期，石藥集團升逾4%！華寶基金港股通創新藥ETF（520880）再收半年線！","url":"https://stock-news.laohu8.com/highlight/detail?id=2664231028","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664231028?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 10:52","pubTimestamp":1788403920,"startTime":"0","endTime":"0","summary":"9月3日，港股创新药链继续活跃，创新药龙头公司领涨，石药集团、中国生物制药双双涨超4%。纯正创新药指数——恒生港股通创新药精选指数一度冲高逾2%，跟踪该指数的港股通创新药ETF华宝盘中再收半年线。中金公司提示，创新药较多公司进入临床数据验证阶段，值得自下而上关注。据统计，港股通创新药ETF华宝覆盖的48家创新药研发公司中，31家上半年实现盈利，归母净利同比正增长的有33家，占比近7成。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-09-03/doc-iniqpkry1034045.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2039709279.SGD","01093","IE00BZ08YR35.GBP","IE00BZ08YT58.USD","LU0501845795.SGD","IE0008368742.USD","LU1226288170.HKD","IE00B031HY20.USD","LU0326950275.SGD","LU0140636845.USD","LU1152091168.USD","LU1993786604.SGD","BK1515","IBBQ","LU1152091754.HKD","LU1226287529.USD","159992","LU1226288253.USD","LU1328277881.USD","IE0008369823.USD","LNGR","LU1813983027.USD","IE00B5MMRT66.SGD","LU0314109678.HKD","BK1521","LU1226287792.SGD","IE00B543WZ88.USD","LU0315179316.USD","520880","LU0072913022.USD","BK1161","LU1226287875.USD","FLHK","BK1191","IE00BZ08YS42.EUR","159316","LU1807302812.USD","KURE","SG9999004220.SGD","LU1008478684.HKD","06978","LU1951186391.HKD","LU0880133367.SGD","LU1960683339.HKD","LU0067412154.USD","MEDX","HK0000165453.HKD","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664463098","title":"摩根大通投行聯席負責人：併購交易業務有望迎來創紀錄年份。","url":"https://stock-news.laohu8.com/highlight/detail?id=2664463098","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664463098?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 02:58","pubTimestamp":1788375516,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IEFN","IBBQ","VXF","IYH","DFMC","AAUM","PGF","GTPE","BK4582","RSPH","PEVC","MMID","TMED","PSP","TBXU","UYG","FFSM","BK4588","BK4585","PBPH","CANC","RFG","MNA","XLFI","ACTV","PRVT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664810334","title":"首個國產IL-17A/F雙靶點抑制劑獲批，這一40年來「有研究無產品」的靶點迎臨床突破｜掘金創新藥","url":"https://stock-news.laohu8.com/highlight/detail?id=2664810334","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664810334?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 22:37","pubTimestamp":1788359868,"startTime":"0","endTime":"0","summary":"半月临床试验动向根据医药魔方提供的数据，8月15日至8月28日，国家药品监督管理局药品审评中心（CDE）共披露195条创新药临床试验登记信息，其中53条为Ⅱ期及以上的关键临床试验。8月15日至8月28日，国家药品监督管理局批准8款创新药上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609023863103683.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609023863103683.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LNGR","MEDX","159992","BK1161","IBBQ","BK1574","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664081495","title":"創新藥半年報冰火兩重天：百濟神州一款藥賣了161億元、六成藥企還在求生 ，「賣藥」仍是終極命題","url":"https://stock-news.laohu8.com/highlight/detail?id=2664081495","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664081495?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 20:48","pubTimestamp":1788353325,"startTime":"0","endTime":"0","summary":"2026年上半年财报季收官，中国创新药产业交出了一份分水岭式的答卷。行业正在告别烧钱讲故事的阶段，走向赚钱才是硬道理的价值兑现期。这种转变并非行业普涨，而是由商业化放量、出海授权爆发、资金来源多元化三重动力共同推动的分化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609023862982990.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609023862982990.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4585","ONC","LU0588546209.SGD","BK1583","BK4139","BK1161","IBBQ","LU1719994722.HKD","LU1770034418.SGD","LU2328871848.SGD","06160","LU1251922891.USD","BK0239","BK4588","06978","MEDX","BK1500","LU1969619763.USD","LNGR","159992","LU0828237510.HKD","BK1588","KURE","BK1574","LU0228659784.USD","688235","LU0307460666.USD","BK4526","LU1303224171.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664811365","title":"歐康維視生物-B(01477)：OT-211 III期臨床試驗完成患者入組","url":"https://stock-news.laohu8.com/highlight/detail?id=2664811365","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664811365?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 20:14","pubTimestamp":1788351299,"startTime":"0","endTime":"0","summary":"欧康维视生物-B公布，OT-211在中华人民共和国开展的III期临床试验已于近日完成合共398名患者的入组。2026年3月，OT-211于中国的III期临床试验完成首例患者入组，标志着 OT-211在中国的临床开发取得重要里程碑进展，并体现了本集团致力于为DED患者推进创新疗法。OT-211已于2025年5月28日获FDA批准用于治疗DED的体征及症状。本次OT-211的成功入组标志着公司与Alcon集团在新药开发领域也形成了强有力的合作与绑定，为后续新药共同探索与开发打下基础。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491179.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["MDTX","BK1574","BMED","PSYK","IBBJ","IBBQ","01477","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664194548","title":"安進（AMGN）罕見病藥物Tavneos將於27年3月1日被徹底撤銷英國上市許可","url":"https://stock-news.laohu8.com/highlight/detail?id=2664194548","media":"金吾财讯","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664194548?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 19:59","pubTimestamp":1788350357,"startTime":"0","endTime":"0","summary":"金吾财讯 | 英国药品监管机构MHRA宣布，暂停安进（AMGN）罕见病药物Avacopan Vifor（原商品名Tavneos）用于新患者，监管认定支撑该药物获批的关键临床试验数据已不可靠。该药2022年在英国获批，用于治疗两种罕见血管炎症自身免疫病。安进持有美国地区权益，由CSL集团（CSLLY）旗下CSLVifor负责英国等海外市场销售。新规9月1日落地，不再允许新患者启用该药物；为保障现有患者安全，设置6个月过渡用药期，2027年3月1日将彻底撤销其英国上市许可，现有患者可在此期间逐步更换替代治疗方案。安进方面公开表示不认可监管机构的决定，担忧该举措会对罕见病患者造成负面影响。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210625/OTU2NGE4NGJmZTIzZDc2N2YxYmJkM2MyMjUzODQzOTQ1NzY=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210625/OTU2NGE4NGJmZTIzZDc2N2YxYmJkM2MyMjUzODQzOTQ1NzY=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"305627","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","LU0109394709.USD","AZNH","AMGN","IE00B4R5TH58.HKD","LU0122379950.USD","LU1571399168.USD","PBE","LU2112291526.USD","BK4533","LU0058720904.USD","LU2468319806.SGD","LU2089984988.USD","PJP","BK4588","IBB","LU0320765992.SGD","LU1057294990.SGD","LU2242652126.USD","LU0289739699.SGD","LU0868494617.USD","LU1061106388.HKD","BK4581","SG9999001440.SGD","TBXU","IE00BFTCPJ56.SGD","IPOS","BK4566","LU1983299246.USD","IE0002141913.USD","IE00BJJMRZ35.SGD","BK4139","LU2242646821.SGD","BBH","BIB","IBBQ","IE00B2B36J28.USD","IE0009355771.USD","IE00BJT1NW94.SGD","BK4599","BK4534","BK4585","LU1023059063.AUD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664819950","title":"海西新藥：已提交自研創新藥HX9428臨床試驗申請","url":"https://stock-news.laohu8.com/highlight/detail?id=2664819950","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664819950?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 19:53","pubTimestamp":1788349980,"startTime":"0","endTime":"0","summary":"9月2日，海西新药（02637）发布公告，公司自主研发的创新药项目HXP056之候选药物分子HX9428，已于2026年8月31日正式向国家药监局药品审评中心递交新适应症糖尿病性黄斑水肿的IIa期新药临床试验申请。HX9428是海西新药自主研发的全新口服小分子创新药物，拟用于治疗nAMD、DME及RVO等血管性视网膜相关疾病。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609023862943252.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609023862943252.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","PSYK","BK1161","IBBJ","IBBQ","BMED","BK1574","MDTX","LNGR","159992","MEDX","06978","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664815045","title":"諾華集團：高效口服BTK抑制劑瑞米布替尼在III期RMS臨床試驗中顯著降低複發率 安全性表現良好","url":"https://stock-news.laohu8.com/highlight/detail?id=2664815045","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664815045?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 19:11","pubTimestamp":1788347485,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4585","IE0002141913.USD","BK4532","IE00BJJMRZ35.SGD","NVS","BK4588","IE00B2B36J28.USD","IE00B4R5TH58.HKD","PPH","BK4578","MDTX","MEDX","IE00BFTCPJ56.SGD","LU0208291251.USD","LU0320765489.SGD","IE00BJT1NW94.SGD","IBBJ","LU0070302665.USD","PSYK","BK4007","IE0009355771.USD","LU0211331839.USD","IBBQ","BMED"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664818429","title":"眾生藥業(002317.SZ)：昂拉地韋片新增適應症臨床試驗申請獲受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2664818429","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664818429?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 17:59","pubTimestamp":1788343190,"startTime":"0","endTime":"0","summary":"智通财经APP讯，众生药业(002317.SZ)发布公告，近日，公司控股子公司广东众生睿创生物科技有限公司自主研发的一类创新药物昂拉地韦片新增适应症“治疗高并发症风险甲型流感”的药物临床试验申请获得国家药品监督管理局(NMPA)受理，并收到《受理通知书》。据悉，昂拉地韦片是具有明确作用机制和全球自主知识产权的全球首款流感RNA聚合酶PB2蛋白抑制剂，已于2025年5月获NMPA批准上市。此次昂拉地韦片新增适应症拟开展III期临床研究入组12岁及以上青少年和成人甲型流感参与者，评估昂拉地韦片治疗甲型流感病毒感染且存在流感相关并发症高风险参与者的有效性和安全性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491021.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0077","BMED","BK0239","002317","BK0188","IBBJ","PSYK","IBBQ","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664897083","title":"國家藥監局正式啓動滴眼劑一致性評價工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2664897083","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664897083?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 17:13","pubTimestamp":1788340392,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IBBQ","MDTX","PSYK","BMED","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664891714","title":"高盛9月「確信名單」更新：美股納入福泰製藥(VRTX.US) 歐股力推萊茵、Adyen和塔蘭克斯","url":"https://stock-news.laohu8.com/highlight/detail?id=2664891714","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664891714?lang=zh_tw&edition=fundamental","pubTime":"2026-09-02 15:20","pubTimestamp":1788333621,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4585","LU0868494617.USD","BK4127","LU0251131958.USD","LU0432979614.USD","LU2471134952.CNY","LU0868494708.USD","IE00B19Z9P08.USD","LU1144417596.USD","SG9999001176.SGD","LU1668664300.SGD","TBXU","LU0289739699.SGD","IE00BZ9MQY76.HKD","LU1791807156.HKD","LU0096364046.USD","BK4550","IBBQ","IBB","LU2237443978.SGD","LU1674673691.USD","IDNA","IE0002141913.USD","IE0009355771.USD","IEV","LU1868837300.USD","BK4588","PBE","LU2237438978.USD","BK4533","BIB","LU2462157665.USD","LU1868836591.USD","LU2471134523.USD","LU2468319806.SGD","LU2324357040.USD","GNMX","IE00BJJMRZ35.SGD","LU2237443549.SGD","VRTX","LU0942090050.USD","LU1868836914.USD","IE00B19Z9Z06.USD","BBH","LU0061475181.USD","SG9999001176.USD","GSX","VXUS","LU2456880835.USD","VGK"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":11,"pageCount":9,"totalSize":201,"code":"91000000","status":"200"}]}}